Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma

Clinical trials of neoadjuvant therapy for melanoma have expanded rapidly over the past several years. Preliminary data demonstrate the prognostic value of pathological response, which might have clinical implications for refining the roles of surgery and adjuvant therapy. These clinical questions are under active investigation across many ongoing clinical trials.

Automated summary

In recent years, there has been a rapid expansion of clinical trials on neoadjuvant therapy for melanoma. Preliminary data has shown the prognostic value of pathological response, which could have clinical implications on refining the roles of surgery and adjuvant therapy. These clinical questions are currently being actively investigated in numerous ongoing clinical trials.